Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5239 - Feasibility of Routine Collection of Health State Utilities using EQ-5D in a Breast Cancer Outpatient Clinic


10 Sep 2017


Poster display session


Cancers in Adolescents and Young Adults (AYA);  Bioethical Principles and GCP;  Breast Cancer


Sofia Torres


Annals of Oncology (2017) 28 (suppl_5): v395-v402. 10.1093/annonc/mdx375


S. Torres1, M. Trudeau1, K. Pritchard1, N. Mitsakakis2, N. Li3, M. Krahn2

Author affiliations

  • 1 Department Of Medicine, Division Of Medical Oncology, Sunnybrook Health Sciences Centre, M4N 3M5 - Toronto/CA
  • 2 Toronto Health Economics And Technology Assessment Collaborative, University of Toronto, M5G2C4 - Toronto/CA
  • 3 Imaging Research, Sunnybrook Research Institute, M4N 3M5 - Toronto/CA


Abstract 5239


Routine collection of health state utilities in the clinical setting may produce data more representative of the real-world population for use in cost-utility models and guide decision making. We are currently carrying out a cross-sectional study to assess the feasibility of routine administration of EQ-5D to breast cancer patients in a multidisciplinary oncology clinic, in an academic cancer centre in Ontario, Canada.


English literate women undergoing treatment or on follow-up for their breast cancer (stage I to IV), are being recruited during their scheduled visit to the cancer centre, preferably after completing the implemented routine symptom screening using the Edmonton Symptom Assessment System (ESAS). Consenting patients complete EQ-5D-5L in tablets, followed by a socio-demographic questionnaire and feedback questions pertaining to study conduct. Answers are stored in a research database and linked to diagnostic and treatment data. Feasibility will be assessed primarily by the proportion of patients who fully complete EQ-5D and by their willingness to complete the instrument at each clinic visit.


To date, 474 women were approached; 262 (55%) were eligible and consented to participate (target enrolment: 341). Median age of participants was 56 years (range:28-90); 24% had metastatic disease. All participants were English literate, but 59% were born outside Canada and speak primarily other languages at home. Ninety-eight percent of recruited patients completed EQ-5D, compared with 84% who completed ESAS on the same day (63% completed ESAS voluntarily prior to enrolment; 21% agreed on completing ESAS for study purposes only). Median time for EQ-5D completion was 84 seconds. Most patients (82%) had no problems using the tablet. Willingness to continue to complete EQ-5D at each clinic visit was not affected by disease status (stage I to III versus stage IV) and 74% would “definitely”/”very likely” continue to answer EQ-5D regularly at each clinic visit.


These preliminary results indicate that routine collection of EQ-5D in clinical practice might be feasible, although the completion rate might be overestimated by the cross-sectional design of the study.

Clinical trial identification

Legal entity responsible for the study

Sofia Torres




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.